- $196.39m
- $200.62m
- $52.84m
Apyx Medical Corp expected to post a loss of 7 cents a share - Earnings Preview
Brief: Apyx Medical Corporation Announces FDA 510(K) Clearance For The Renuvion® Micro Handpiece
Apyx Medical Corp reports results for the quarter ended in March - Earnings Summary
Brief: Apyx Medical Corporation Reports Q1 2023 Financial Results, Updates FY 2023 Financial Outlook
Apyx Medical Corp expected to post a loss of 13 cents a share - Earnings Preview
Brief: Renuvion Receives FDA Clearance For Specific Use After Liposuction
Brief: Apyx Medical Corporation Receives FDA 510(K) Clearance For Use Of Renuvion
Apyx Medical Corp reports results for the quarter ended in December - Earnings Summary
Brief: Apyx Medical Corporation Reports Fourth Quarter And Full Year 2022 Financial Results Introduces Full Year 2023 Financial Outlook
Apyx Medical Corp expected to post a loss of 14 cents a share - Earnings Preview
Brief: Apyx Medical Corporation Receives FDA Clearance For The Use Of Renuvion To Coagulate And Contract Soft Tissues, Including Subcutaneous Tissue, Where Needed
Brief: Apyx Medical Announces New 5-Year Credit Agreement With Midcap Financial
Brief: Apyx Medical Reports Preliminary Fourth Quarter And Full Year 2022 Revenue Results
Brief: Apyx Medical Corp Files For Mixed Shelf Of Up To $100 Mln - SEC Filing
U.S. RESEARCH ROUNDUP-Expensify, NVIDIA, Signature Bank
Apyx Medical nosedives after slashing FY22 revenue forecast
Apyx Medical Corp reports results for the quarter ended in September - Earnings Summary
Brief: Apyx Medical Corporation Reports Q3 2022 Results
Apyx Medical Corp expected to post a loss of 14 cents a share - Earnings Preview